News

Now Open: VITAS® Healthcare Inpatient Hospice Unit in Fort Worth

Freestanding homelike facility for specialized end-of-life care will serve 500+ patients annuallyFORT WORTH, Texas, Jan. 08, 2025 (GLOBE NEWSWIRE) --…

12 months ago

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE…

12 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed…

12 months ago

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology

Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive…

12 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE)…

12 months ago

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and…

12 months ago

Collegium Provides 2025 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue…

12 months ago

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on…

12 months ago

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder ValueWARRINGTON, Pa., Jan. 08, 2025…

12 months ago

Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into…

12 months ago